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Abstract
Background: Measurement-based care is an evidence-based practice for depression that efficiently identifies
treatment non-responders and those who might otherwise deteriorate [1]. However, measurement-based care is
underutilized in community mental health with data suggesting fewer than 20 % of behavioral health providers
using this practice to inform treatment. It remains unclear whether standardized or tailored approaches to
implementation are needed to optimize measurement-based care fidelity and penetration. Moreover, there is
some suggestion that prospectively tailored interventions that are designed to fit the dynamic context may
optimize public health impact, though no randomized trials have yet tested this notion [2]. This study will
address the following three aims: (1) To compare the effect of standardized versus tailored MBC implementation on
clinician-level and client-level outcomes; (2) To identify contextual mediators of MBC fidelity; and (3) To explore the
impact of MBC fidelity on client outcomes.
Methods/design: This study is a dynamic cluster randomized trial of standardized versus tailored measurement-based
care implementation in Centerstone, the largest provider of community-based mental health services in the USA. This
prospective, mixed methods implementation-effectiveness hybrid design allows for evaluation of the two conditions
on both clinician-level (e.g., MBC fidelity) and client-level (depression symptom change) outcomes. Central to this
investigation is the focus on identifying contextual factors (e.g., attitudes, resources, process, etc.) that mediate MBC
fidelity and optimize client outcomes.
Discussion: This study will contribute generalizable and practical strategies for implementing systematic symptom
monitoring to inform and enhance behavioral healthcare.
Trial registration: Clinicaltrials.gov NCT02266134.
Background
Depression is one of the world’s leading causes of illness
burden [3], costing the United States alone over $80 bil-
lion annually due to lost work and wages [4]. There are
now many evidence-based practices (EBPs) for the
treatment of depression, but these practices remain
largely unavailable to clients receiving services in com-
munity mental health centers (CMHCs). One reason for
this paucity of EBPs is that CMHCs have few resources
available for the intensive training plus consultation op-
portunities that appear necessary to retrain therapists in
complex EBPs such as Cognitive Behavioral Therapy
(CBT; e.g., [5–7]). Moreover, CMHC therapists bring
unique values, attitudes, and skill sets that often misalign
with EBPs such as CBT (e.g., [8, 9]). The traditional ap-
proach to improving client care—integrating a complex,
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multi-component EBP like CBT into care delivery—is
faced with significant challenges.
Conversely, measurement-based care (MBC) is a rela-
tively simple evidence-based intervention framework [10].
MBC, by definition, is the practice of using routine symp-
tom measurement to inform treatment [11]. MBC is an
evidence-based framework that has established effective-
ness, broad reach, and multifaceted utility for enhancing
usual care. In terms of effectiveness, MBC has been shown
to improve depressed client outcomes with medium-effect
size improvements over usual care [12, 1, 13]. A meta-
analysis indicated that MBC is particularly effective for im-
proving outcomes when depressed clients are not
demonstrating progress and by reducing client deteri-
oration [1, 14]. In terms of reach, MBC has greater
reach potential than complex EBPs (e.g., CBT) that
involve multiple theory-specific components targeted
at single disorders. MBC has transtheoretical (relevant
for use by clinicians regardless of background) and
transdiagnostic (effective in enhancing usual care for
numerous disorders) relevance [11]. We conceptualize
MBC as a minimal intervention needed for change
(MINC; [15]) as it may optimize diverse usual care
offerings for depression by enhancing the clinician’s
ability to target session interventions to clients’ unique
symptom profiles and needs without requiring clinicians
undergo months of retraining or shed their established
theoretical orientation [11].
In terms of utility, MBC aligns with the Patient
Protection and Affordable Care Act (P.L. 111–148)
by focusing on monitoring outcomes and satisfying
meaningful use requirements [16]. MBC presents a
systematic approach for selecting and adapting inter-
ventions [17] by flagging clients who are not improv-
ing and highlighting treatment targets [13]. The
National Institute of Mental Health’s (NIMH) nationwide
public health clinical trial, the STAR*D (Sequenced
Treatment Alternatives to Relieve Depression), demon-
strated MBC’s utility for guiding both medication and
psychotherapeutic interventions [18]. MBC also has
established utility for promoting care coordination
across disciplines [19]. Finally, MBC provides the basis
for evaluating subsequent EBP implementation efforts
through a foundation of outcome monitoring, which
can be built into the soon to be ubiquitous electronic
health record technologies.
Despite MBC’s demonstrated effectiveness, reach, and
utility, recent estimates suggest that fewer than 20 % of
PhD level clinicians, master level clinicians, and psychia-
trists routinely measure mental health symptoms prior
to each session [20–22]. MBC has great potential for im-
plementation success by design, yet barriers such as atti-
tudes and feasibility exist [23], and a gap remains
between documented MBC effectiveness and use in
practice. Previous attempts to integrate MBC into real
world settings have focused on the development of stan-
dalone feedback systems [24]. Few studies have investi-
gated the strategies necessary to integrate MBC into
community mental health while (1) interfacing MBC
with existing system requirements and clearly delineat-
ing the necessary implementation strategies and (2) tak-
ing into account stakeholder perceptions and needs
when building the implementation approach.
Current study
The long-term goal of this research project is to pro-
vide generalizable and practical recommendations
about strategies that promote MBC implementation, fi-
delity, and sustainment in CMHCs. To realize this goal,
this study will test a standardized versus a tailored ap-
proach to implementing MBC at Centerstone, the lar-
gest provider of community-based mental health services
in the USA. In this study, MBC will center on administra-
tion of the Patient Health Questionnaire-9 Item Version
[25]. The PHQ-9 contains nine items that map directly
onto the symptoms of a major depressive episode (DSM-
IV TR; [26]) (e.g., trouble sleeping, little interest) and one
item pertaining to impairment. The PHQ-9 thus provides
a depression severity score capturing the previous 2
weeks. The PHQ-9 is one of the best-validated depression
measures used in over 1000 research studies [27]. The
PHQ-9 has depression severity cutoff scores, is sensitive
to change [28], and is useful for weekly administration as
an indicator of treatment effectiveness [29]. Three diag-
nostic meta-analyses and a recent review have confirmed
the good sensitivity and specificity of the PHQ-9 in mak-
ing a major depressive disorder diagnosis [27].
Although touted as superior, tailored implementations
have rarely been compared to standardized approaches
[30, 31]. Moreover, recent research has demonstrated a
need to adapt EBPs to fit the specific context in which
they are being implemented, particularly if they are to be
sustained [32]. This proposal reflects a movement in the
field of implementation science to compare planned EBP
adaptations to standardized EBP approaches [2, 33]. This
study is a mixed methods implementation-effectiveness
hybrid evaluation of a standardized versus tailored ap-
proach to MBC implementation on both clinician-level
(e.g., MBC fidelity) and client-level (depression symptom
change) outcomes. Central to this investigation is the
need to identify contextual factors (e.g., attitudes, re-
sources, process, etc.) that mediate MBC fidelity and
optimize client outcomes.
Primary guiding model
The Framework for Dissemination [34] is the study’s guid-
ing conceptual model as it is derived from the best avail-
able implementation research and includes a three-phase
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evaluation process for use with academic-community
partnerships (see Fig. 1). The context of diffusion within
this model highlights six domains theorized to determine
successful implementation (see Fig. 1, Box 1): (1) norms
and attitudes, (2) structure and process, (3) resources, (4)
policies and incentives, (5) networks and linkages, and (6)
media and change agents.
The first three domains affect the willingness and ability
of stakeholders to implement and sustain new interven-
tions [34]. Norms and attitudes represent the knowledge,
expectations, beliefs and values of stakeholders (e.g., be-
liefs about a novel practice’s value for an organization).
Organizational structure and process reflect the way an
organization is structured and operates to deliver services,
including sets of characteristics such as organizational
mission, size, governance and decision-making processes,
and types of services offered. Resources include the varied
forms of financial, physical, human, social, and political
capital necessary to implement, spread, and sustain new
practices. The other three domains relate to sources of in-
formation and influence through which potential adopters
learn about and assess innovations [34]. Policies and in-
centives constitute rewards or sanctions embedded in
regulatory, funding, and organizational rules and pro-
grams that alter the costs and benefits of adopting a new
service offering (e.g., financial bonuses, opportunities for
enhancing training). Networks and linkages reflect the
conduits among organizational and community partici-
pants that enable the flow of information and social sup-
port around potential adopters (e.g., communication with
other sites or provider organizations, staff relationships).
Finally, media and change agents represent specifically ac-
tive sources of information with credibility related to new
practices or services (e.g., external trainers, consultants, or
internal champions, experts, and cheerleaders).
Taken together, the context of diffusion within the
Framework for Dissemination organizes the evaluation of
key contextual factors that may promote or hinder the
implementation and sustainment of EBPs in CMHCs
[34]. As such, this model will not only allow for an
examination of contextual mediators of implementation
success, but it will also be used to guide the tailored ap-
proach to implementation. Finally, the model will drive
the three-phased evaluation process (see Fig. 1, Row 2):
(1) Capacity/Needs Assessment, (2) Implementation/
Process Evaluation, and (3) Outcome/Impact Evaluation.
Complementary testable model
This study will also test a recently proposed model,
the Dynamic Sustainability Framework (DSF; [2]).
The DSF promotes testing the longstanding hypoth-
esis that program drift from “EBP fidelity” leads to a
voltage drop in client outcomes when results are
compared to effect sizes observed in efficacy trials.
Chambers et al. [2] contend that an alternative hy-
pothesis is important to consider, intentional pro-
spective EBP adaptations informed by stakeholders
and that account for relevant multilevel contextual
factors may optimize implementation, sustainment,
and client outcomes, particularly when adaptations
are made iteratively to fit the dynamic context. The
present study will test this model by comparing a
standardized condition to a tailored condition. The
standardized condition requires (via an implementa-
tion guideline) that MBC be integrated prior to each
and every psychotherapy session according to its doc-
umented efficacy (e.g., [1]), whereas the tailored con-
dition will encourage implementation teams (comprised
of CMHC clinicians, staff, administrators, and research
staff ) to adapt the MBC guideline and implementation by
Fig. 1 Framework of dissemination
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taking into account site-specific contextual factors. Con-
sultation in the standardized condition will be offered to
clinicians with the goal of achieving and maintaining
MBC fidelity, whereas consultation in the tailored condi-
tion will support contextual and intervention changes to
best fit the particular site. This study will address three
specific aims.
Aim 1: To compare the effect of standardized versus
tailored MBC implementation on clinician-level (1a) and
client-level (1b) outcomes. We hypothesize that tailored
implementation will outperform standardized in terms
of (H1a) MBC fidelity and (H1b) reducing client depres-
sion severity.
Aim 2: To identify contextual mediators of MBC fidel-
ity. We hypothesize that contextual mediators (e.g.,
structure, norms, etc.) will be leveraged in the tailored
condition, but serve as barriers in the standardized
condition.
Aim 3: To explore the impact of MBC fidelity on
client outcomes as a preliminary test of the Dynamic
Sustainability Framework [2]. We hypothesize that
adapted MBC protocols (tailored condition) will out-
perform weekly administration of PHQ-9s (standard-
ized condition) with respect to clinically significant
change in depression severity from intake to week 12.
Methods/design
Study context
Centerstone is the largest provider of community-
based mental health services in the USA – delivering
psychotherapy, social work services, psychiatric ser-
vices, and health promotion/disease prevention inter-
ventions to over 140,000 children, families, and adults
each year. Centerstone has a physical presence in
five-states (Tennessee, Indiana, Illinois, Kentucky, and
Florida) and hosts the Knowledge Network (a national
collective of mental health agencies focused on evidence-
based care). Centerstone also maintains the largest reposi-
tory of community mental health data in the USA—con-
taining data from over 350,000 patients, 20 million service
records, and 2 million prescriptions. This “data ware-
house” exists to facilitate mental health services research
and populates an innovative analytics platform (Enlighten
Analytic) to guide clinical decision-making and agency
management. The clinical research, program evaluation,
informatics, and grant writing arm of Centerstone—
Centerstone Research Institute (CRI)—works with the
clinical enterprise to prioritize the standardization of
care through EBP delivery. Centerstone initiated a
partnership with the principal investigator (CCL) in
2011 to develop clinical pathways for depression. A
workgroup, comprised of three regional directors from
clinics across Indiana and Tennessee and the CRI Director
of Clinical Research, convened for monthly meetings over
the course of 2 years. MBC was identified as the EBP of
focus given its relevance and potential utility for improv-
ing client outcomes across diagnoses—a necessary feature
given the highly complex and comorbid presentations of
Centerstone clientele.
Conditions
Overview of the blended implementation protocol
Both conditions (standardized and tailored) will employ
the same blended protocol of implementation strategies
(i.e., combination of discrete strategies [35]) to remove
time and resource confounds (e.g., ensure differences
across conditions are not due to one having more train-
ing). The blended protocol of implementation strategies
was defined using the guiding model (Framework for
Dissemination [34]), the best available literature on pro-
moting MBC implementation (e.g., [13, 36–41]), the
MBC intervention framework, the partnership goals, and
the pilot study results. Table 1 depicts and describes the
protocol and unique focus of the implementation strat-
egies across conditions. The order of strategies will
proceed as follows within each site’s active implementa-
tion period: (1) embed PHQ-9 in electronic health rec-
ord; (2) conduct needs assessment; (3) offer initial
training; (4) set guidelines; (5) form implementation
team; (6) conduct triweekly group consultation meet-
ings. Following the active implementation phase, the
implementation team will be encouraged to continue to
meet to promote sustainment. A similar blended proto-
col of implementation strategies led to successful MBC
implementation using the PHQ-9 with 90 % completion
with over 30,000 clients each quarter at Group Health
Cooperative, a consumer-governed, non-profit, health
care system in Washington and Idaho [40].
The standardized condition includes all aforemen-
tioned strategies in the order listed above and de-
scribed in Table 1. Tailored implementation refers to
the responsive application of implementation strategies
and content matched to determinants of practice (i.e.,
barriers) identified via a needs assessment and forma-
tive evaluations. The same strategies outlined in the
standardized condition will be employed in the tai-
lored condition (Table 1); however, the content will
be tailored to the context of each site. The needs as-
sessment will employ rapid ethnography methods to
reveal contextual factors that may serve as barriers to
the implementation process. The results of the needs
assessment will be shared with a site’s implementation
team, which will convene to adapt and define the
site-specific guidelines for PHQ-9 completion and
other intervention components. For instance, it may
be that Site X decides that monthly PHQ-9 adminis-
tration is optimal with respect to feasibility and clin-
ical utility. Conversely, Site Y may prefer to have
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clients complete the PHQ-9 every other session. As
described in Table 1, training will be offered to all
enrolled clinicians using tailored materials that will
target the identified barriers from the needs assess-
ment. For instance, if clinicians at a particular site
perceive the PHQ-9 to be irrelevant to clients, train-
ing content will incorporate client perspectives on its
utility. If clinicians indicate that lack of time is a bar-
rier, then training will incorporate experimentation to
streamline review and discussion of scores. Different
members of the investigative team will lead training
and consultation in the two conditions to ensure
differentiation. A contamination interview and ana-
lysis will occur at the end of the active implementa-
tion to determine what, if any, crossover occurred
between conditions.
Phases and procedures
Phase 1: randomized trial, implementation and sustainment
The dynamic cluster randomized implementation trial
will be completed across 30 months and include 12 sites
in four cohorts. Each cohort will have 5 months of active
implementation. Specifically, matched sites (based on
size and urban/rural status) are randomized to either early
Fig. 2 Study design
Table 1 Standardized versus tailored protocol and focus
Contextual
factor
Implementation strategies Standardized focus Tailored focus
Resources Paper-based PHQ-9 with score entered in
EHR for clinician review
Client completion of PHQ-9 on paper
and score entered in EHR for review by
the clinician
Client completion of PHQ-9 on paper




Form implementation teams for each site
consisting of the site administrator, a
clinician identified as an opinion leader, a
self-nominated MBC champion, an office
professional staff member, and research staff
using data from the initial needs assessment.
Each team will meet triweekly over the
course of the active implementation period
Team meetings focus on monitoring and
promoting MBC fidelity per the guideline




Guideline for PHQ-9 administration frequency Each session w/client Determined by site
Norms and
attitudes
Initial MBC training Standardized training material Tailored training material targeting




Progress note modifications For clinician score review For clinician score review
Media and
change agents
Triweekly consultation with experts Consultation focuses on MBC fidelity,
particularly on incorporating clinician
PHQ-9 score review into sessions,
encouraging discussion of scores with
clients, and providing tips on targeting
lack of progress
Consultation focuses on targeting
identified barriers in addition to MBC
fidelity. However, emphasis will be placed
on tailoring review, discussion, and targeting l
ack of progress to the site-specific PHQ-9
guidelines to address contextual and other
barriers as they are identified throughout
the course of implementation
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or later stage implementation in four cohorts (2–4 sites
per cohort spaced 5 months apart), with half the sites ran-
domized to the standardized and half to the tailored con-
dition (Fig. 2). The timing of this protocol is based on the
published work of Miller et al. [42] as well as the success-
ful naturalistic MBC implementation at Group Health
[40]. Table 2 provides an outline of the steps that will
occur in Phase 1. All of the listed steps will be repeated
across each of the four cohorts.
Phase 2: post hoc characterization of MBC fidelity
Consistent with the Dynamic Sustainability Framework
[26], the approach to MBC implementation may be
adapted by sites in the tailored condition. Therefore,
characterizing fidelity for the tailored condition will need
to reflect the guideline established for each site. The
steps of Phase 2 are delineated in Table 2.
Site selection and randomization
Fifty Centerstone sites were examined for eligibility from
Tennessee and Indiana based on criteria such as size (>5
clinicians providing individual psychotherapy to depressed
adult clients) and rural versus urban status. Twelve sites
were matched using three characteristics: number of clini-
cians, number of adult depression diagnoses, and urban
versus rural status. A dynamic cluster randomization trial
was selected to enhance feasibility of capacity management
[43]; the design dictated four time cohorts (see Fig. 2). Prior
Table 2 Implementation Phases I and II overview
Evaluation aim Evaluation activities
Phase 1: randomized trial, implementation and sustainment
Needs assessment (AT1; Fig. 1, Box
1)
Engage in the baseline mixed methods needs assessment
(a) A subset of clinicians (N = 5–8) identified via purposive sampling representing extreme variation will
participate in a 1.5-h focus group
(i) Rapid Ethnography will then be used to uncover site-specific insights that will guide the content of training
and consultation in the tailored condition only
(b) All enrolled clinicians will complete the battery of baseline measures (Table 3)
Implementation teams form
(a) Opinion leaders (Childers, 1986) and self-nominated MBC champions will be identified from the needs
assessment
Clinicians Participate in 4-h MBC training workshop
Implementation teams convene triweekly and optional consultation offered to participating clinicians
(a) Implementation team meetings and consultation sessions will be audio-recorded and coded
(see Additional file 1).
(b) A site-specific team member will also log meetings (using Additional file 1) and the data will be triangulated
to evaluate consistency across sites
Implementation/process evaluation
(AT2; Fig. 1, Box 2)
Engage in mixed methods reassessment
(a) Conduct an additional round of focus groups with clinicians
(b) Re-administer the baseline surveys to clinicians
Site implementation teams encouraged to continue to meet to promote MBC sustainment without the research
personnel present
Outcome/impact evaluation
(AT3; Fig. 1, Box 3)
Engage in mixed methods reassessment
(a) Conduct an additional round of focus groups with clinicians
(b) Re-administer the baseline surveys to clinicians
Conduct focus groups with implementation team to review their experience and site progress since the research
personnel exited the team.
Phase 2: post hoc characterization of MBC fidelity
Outcome/impact evaluation Measure MBC fidelity via data collected in the electronic health record
(a) Clinician reported client PHQ-9 scores
(b) A report to indicate whether the clinician looked at the scores
(c) Clinician self-report of whether they discussed the PHQ-9 scores with the client
Triangulate MBC fidelity outcome with client post-session text message surveys and objective therapy session coding
Focus group data formally coded for mixed method analysis
Note: AT1 = assessment time 1—prior to MBC implementation; AT2 = assessment time 2–5 months after the needs assessment; AT3 = assessment time 3–10
months after implementation/process evaluation or 15 months after the baseline needs assessment
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to randomization, the number of sites for each of the four
time cohorts was determined as follows: 2, 4, 4, and 2.
Randomization was implemented following Chamberlain
et al. [44] and Brown, et al. [45] who employed a similar se-
quential design. Sites were first randomized into eight site
clusters to fill the eight cells in the design (4 time cohorts ×
2 conditions). Cluster assignment was optimized through
assigning sites to 10,000 random permutations of eight site
clusters, four with one and four with two sites. The random
assignment with the smallest distance was selected as the
optimal set of site cluster (i.e., the randomly created site
cluster combination with the greatest similarity in site clus-
ters was selected). Next, site clusters were randomly
assigned to one of the four time cohorts and then, within
the time cohort, site clusters were randomly assigned to the
standardized or tailored condition.
Participants
Clinician inclusion criteria
A total of 187 clinician participants will be recruited
across 12 sites (target N = 150). The number of sites and
clinicians was determined by a simulation-style power
analysis to detect a small effect size. Within each en-
rolled site, clinicians will have the option to participate if
they (1) are at least 40 % full-time equivalent, (2) provide
individual psychotherapy, (3) treat adults with depres-
sion, and (4) conduct sessions in English.
Clinician data collection
Table 3 summarizes the clinician battery and assessment
time points: Baseline Needs Assessment (AT1, prior to
MBC implementation); Implementation/ Process Evalu-
ation (AT2, 5 months in, following the active implemen-
tation phase; Additional file 1); and Outcome/ Impact
Evaluation (AT3, 15 months in, 10 months after research
personnel have ceased active involvement). Each contextual
factor of diffusion [28] will be assessed via self-report and
qualitatively via focus groups with a subset of clinicians.
MBC fidelity is the main clinician-level implementation
outcome. Barriers to PHQ-9 completion will also be col-
lected for the first 5 months of implementation via clinician
self-report within the electronic health record.
Client recruitment
A total of 625 depressed adult clients (target N = 500)
will be recruited for enrollment in this study; approxi-
mately three clients will be recruited per participating
clinician. As this is a pragmatic trial [46], client partici-
pation criteria is very inclusive: (1) age 21 and above;
(2) depression is one of the primary treatment foci
based on clinician diagnosis (e.g., major depressive dis-
order, dysthymic disorder, depressive disorder NOS, ad-
justment disorder with depressed mood); (3) significant
depressive symptom severity (PHQ-9 total score >9
reflecting moderate depression); (4) receipt of individual
psychotherapy; (5) fluency in English; (f) new client begin-
ning treatment; and (6) client is receiving services from an
enrolled study clinician during the proposed funding
period. Exclusion criteria are minimal, an inability to sign
the consent due to lack of competence or inability to read.
CRI staff will identify eligible clients via nightly elec-
tronic health record queries. Clients will be contacted by
telephone and administered the PHQ-9 [25] to confirm
eligibility prior to their first therapy session. Only clients
scoring greater than 9 (reflecting at least moderate de-
pression) on the PHQ-9 will be invited to participate.
Once a client has been enrolled, the study team will flag
the client in the electronic health record to initiate study
procedures for the clinician.
Client data collection
The goal of client data collection is to determine if the
measurement schedules and use of MBC by clinicians in
the standardized versus tailored conditions have differ-
ential effects on depression symptom outcomes. Clients
will be invited by participating clinicians to complete the
PHQ-9 in the waiting room according to site-generated
guidelines (prior to each session in the standardized con-
dition, site-specific schedule in the tailored condition).
Client PHQ-9 responses will be entered into the elec-
tronic health record by clinicians to enable review of
scores over time (via a graphical interface) and to facili-
tate discussion of symptom trajectories in session. Given
that this is an implementation trial, there is potential for
variance in the completion/administration of the PHQ-9
instrument. To enhance data quality, enrolled clients in
both conditions will complete the PHQ-9 at baseline
and at week 12 of treatment in a phone call with study
staff. The 12-week window reflects a commonly used
time period in randomized clinical trials during which
depressive symptoms are expected to remit. We will also
supplement active research data collection with regularly
collected administrative data (e.g., multiaxial psychiatric
diagnoses, employment status, medication, etc.) captured
in intake and progress review reports in the electronic
health record. Finally, to substantiate the clinician self-
report of PHQ-9 integration into the session, the client
will be asked to respond to five-item text message sur-
veys immediately following each session inquiring about
clinician MBC fidelity.
Aim 1:
To compare the effect of standardized versus tailored MBC
implementation on clinician-level (1a) and client-level (1b)
outcomes
We hypothesize that tailored implementation will out-
perform standardized in terms of (H1a) MBC fidelity
and (H1b) reducing client depression severity.
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Table 3 Quantitative clinician measures: potential contextual mediators
Construct Description Time point (month)
0 5 15
Demographics An adapted 16-item version of the one developed by Lewis & Simons (2011) to assess
clinician demographic information (e.g., age, gender, ethnicity) as well as training (e.g.,
degree level, measurement-based care training) and treatment (e.g., theoretical orientation,
caseload) information
X
Norms A 6-item measure of subjective (3 items) and descriptive (3 items) norms developed based on the
guidelines and considerations put forth by theory of planned behavior measurement development
manuals (Azjen, 2006; Francis et al., 2004)
X X X
Attitudes Monitoring and Feedback Attitudes Scale (MFA; Jensen-Doss, Becker, Smith, Lyon, Lewis, Stanick,
& Hawley, in prep) is a 17-item measure of clinician’s attitudes about “‘routine’ progress monitoring
and providing feedback to clients about treatment progress.” It has demonstrated good internal
consistency and consists of three scales: MFA Benefit, MFA Harm, and MFA Trust
X X X
Evidence-based practices attitudes scale (EBPAS; Aarons, 2004) is a 15-item measure of clinician’s
attitudes toward adopting evidence-based practices, consisting of one total score and four scales:
Appeal, Requirements, Openness, and Divergence. It has demonstrated good psychometrics,
displaying good internal consistency (Aarons, 2004; Aarons et al., 2007) and construct and convergent
validity (e.g., Aarons et al., 2007; Aarons, 2004; Aarons & Sawitzkey, 2006; Aarons, 2006)
X X X
Culture & Climate Survey of Organizational Functioning (TCU SOF; Broome et al., 2007) is 162-item measure of an
organization’s resources, job attitudes, readiness to change, workplace practices, climate, and training
exposure and utilization. The SOF is comprised of 32 scales, which includes 23 scales from the
Organizational Readiness for Change (ORC; Lehman et al., 2002) measure and nine additional scales
measuring workplace practice and job attitudes, with all of these scales demonstrating acceptable
psychometrics (e.g., Broome et al., 2007; Broome et al., 2009; Lehman et al., 2002).
X X X
Implementation Climate Scale (ICS; Ehrhart, Aarons, & Farahnak, 2014) is an 18-item measure assessing
a clinician’s perception of the strategic climate of the organization, specifically the facets of the
organizational climate that are essential for successful implementation of EBPs. It consists of a total
score and six factors: Selection for openness, Recognition for EBP, Selection for EBP, Focus on EBP,
Educational Support for EBP, and Rewards for EBP. It has displayed sound psychometrics, including
good to excellent internal consistency and construct-based evidence of validity (Ehrhart et al., 2014)
X X X
Structure and process Barriers and Facilitators to Implementing survey (Salyers, Rollins, McGuire, & Gearhart, 2009) is a
21-item measure of the potential barriers and facilitators to implementing an innovation. It contains
a total facilitator score and three subscales: Agency leadership support, Program-level structures, and
Job-related structural supports with two open-ended questions: “What facilitated/helped you provide
MBC?” and “What were the challenges/barriers to providing MBC?” The measure has demonstrated
excellent internal consistency across the three subscales (Salyers et al., 2009)
X X X
Clinic Systems Project (CSP) Director Survey (Schoenwald, Kelleher, Hoagwood, Landsverk, & Glisson,
2003) is a structured interview that will be reduced and adapted for relevance to the study and
conducted with the clinic directors of each site and the executive director. This survey assesses
the infrastructure of the organization and sites, such as staffing, turnover, supervision, services, and
previous implementation practices, and financing. The CSP Director Survey interview also includes
21-items from the Dimensions of Organizational Readiness-Revised (DOOR-R; K. Hoagwood et al.,
2003), which asks the director to rate the domains or factors (e.g., management support, treatment
fit or match with the organization’s mission) s/he perceives to be critical for successful implementation
of new treatments and services
X
Policies and incentives Qualitative Focus Groups will be used to explore the domain of Policies and Incentives
(see Additional file 2), as no quantitative measures exist
X X X
Resources Survey of Organizational Functioning (TCU SOF; Broome et al., 2007)’s Resources scale is a 25-item
scale from the SOF. The scale has five subscales: Offices, Staffing, Training, Computer Access, and
e-Communications
X X X
Networks and linkages Sociometric Questionnaire (Valente et al., 2007) is a 3-item sociometric questionnaire that will be given
to identify professional, personal, and advice relations among staff (Valente, Chou, & Pentz, 2007) and
calculate the density and centrality of the network. The three questions will include: a) “Which clinician
is a colleague you go to as a source of information on client care-related matters;” b) “Which clinician
is a colleague with whom you discuss you clinical work;” and c) “Which clinician is a colleague with
whom you are friends?” The questionnaire will be paired with an alphabetized roster of all of the
clinicians at each site, in which the respondent designates his or her relationship with each individual.
An adjacency matrix will be used to record information about the relationships or ties between each
pair of clinicians (Wasserman & Faust, 1994). This information will then be entered into social network
analysis software , which will allow for measurement of network metrics, in particular
centrality and density
X X X
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Quantitative measures
MBC fidelity
Data pertaining to MBC fidelity will be collected via
three mechanisms: (1) clinician report in the electronic
health record; (2) client report via text messaging; and
(3) objective coding of a subsample of clinician-client
sessions. The trichotomous fidelity outcome variable will
be computed using the following data from the elec-
tronic health record as follows: (a) clinician recorded cli-
ent PHQ-9 scores (score 0 = No PHQ-9; 1 = PHQ-9); (b)
a report to indicate whether the clinician looked at the
scores (score 0 = did not review PHQ-9; 1 = reviewed
PHQ-9); and (c) clinician self-report of whether they dis-
cussed the PHQ-9 scores with the client (score 0 = did
not discuss; 1 = discussed with client in session). Overall
MBC fidelity scores can range from 0 to 3 reflective of
“0 = none”, “1 =mild”, “2 =moderate”, and “3 = excellent”
fidelity. This fidelity outcome variable will be triangu-
lated with client post-session text message surveys and
objective session coding as the three reports (clinician,
client, and objective coder) may not align [47, 48].
Client depressive symptom severity: patient health
questionnaire 9-item version (PHQ-9)
In addition to the PHQ-9 serving as the central focus of
the MBC (symptom monitoring), client scores on the
PHQ-9 [25] at baseline and week 12 serve as the primary
effectiveness client-level outcomes.
Statistical analyses
Multilevel generalized linear models will be used to as-
sess hypotheses for standardized versus tailored MBC
implementation for both models of clinician and client
outcomes. The multilevel generalized linear model frame-
work includes continuous outcomes and extends the
linear model to accommodate nonlinear outcomes by
including a distributional assumption and link function
(e.g., a binomial distribution with a logistic link func-
tion will be used to implement logistic models). Specif-
ically, we will examine the effect of the implementation
condition on MBC fidelity (ordered categorical out-
come; range 0–3 reflecting client completion, clinician
review, discussion in session) measured across time.
Multilevel models account for the non-independence of
repeated measurements within participants and non-
independence due to sites [49]. Models for clinician
and client outcomes will be constructed in an identical
manner by following a model building-sequence recom-
mended by Singer and Willett [50] in which (1) empir-
ical growth plots will be examined, (2) an unconditional
means model will be fit, (3) an unconditional linear
growth model will be fit, (4) unconditional nonlinear
growth models (a quadratic model) will be fit, (5) un-
conditional linear and nonlinear growth models will be
compared using the Akaike Information Criterion to
identify the best model of change across time, and (6)
level-2 and level-3 predictors will be added.
Power calculations
A power analysis for the Aim 1 multilevel models was
conducted using Monte Carlo studies in which power is
the proportion of significant effects (2-tailed α = 0.05)
for a parameter of interest across all simulated data sets
fit with the same model [51, 52] using MPlus (version
7). For each model, 10,000 data sets were simulated and
analyzed. Data in the Monte Carlo studies were simu-
lated with the goal of identifying the smallest detectable
effect size with power ≥ 0.80. Dropout was simulated to
reflect an increase of 5 % missing data per wave. Re-
peated measurements were nested within participants
(ICC = 0.50) and participants were nested in sites (ICC =
0.05). Average effect sizes for Aim 1 analyses were com-
puted using an approximation of Cohen’s d for growth
models [53]. Using this metric, the study is sufficiently
powered to detect effect sizes as small as d = 0.46 for
the clinician models (N = 150) and effect sizes as small
as d = 0.30 for the client models (N = 500).
Aim 2:
To identify contextual mediators of MBC fidelity
We hypothesize that contextual mediators (structure,
norms, etc.) will be leveraged in the tailored condition
but serve as barriers in the standardized condition.
Quantitative measures
The dependent variable for Aim 2 is the implementa-
tion outcome of MBC fidelity as described in Aim 1.
The independent variables summarized in Table 3 in-
clude the six factors delineated in the context of diffusion
(norms and attitudes; structure and process; resources;
policies and incentives; networks and linkages; media and
change agents) from the Framework of Diffusion as
Table 3 Quantitative clinician measures: potential contextual mediators (Continued)
Media and change agents Opinion Leadership Scale (OLS; Childers, 1986) is a 6-item opinion leader self-identification scale that
will be employed to identify clinician opinion leaders who may serve as influential change agents.
The six items were adapted for relevance to clinical work and rated by clinicians. It has demonstrated
good internal consistency and validity (Childers, 1986)
X X X
Qualitative Focus Groups will be used to collect information on internal and external media influence
since no quantitative measures currently exits to examine these constructs
X X X
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potential mediators, assessed at baseline (AT1), 5 months
into the implementation process (AT2), and 15 months
into the implementation process (AT3). See Table 3 for a
complete listing of the quantitative measures.
Focus groups
Focus groups will be conducted with 5–8 clinicians at
each site at baseline (AT1) after the active implementa-
tion phase (AT2) and at 10 months post active imple-
mentation phase (AT3). Focus group participants will be
selected in collaboration with the clinic director using
purposive sampling for extreme variation [54]. Focus
groups will serve to identify key barriers to MBC im-
plementation, trace the ways in which they affect or
mediate processes of care and client outcomes, and
evaluate whether these barriers change over the course of
active implementation and sustainment of MBC. We will
develop a focus group script in collaboration with an
expert in qualitative inquiry in order to maximize
information gleaned regarding the Framework for
Dissemination domains highlighted above (Additional
file 2). Equal number of questions will be presented
to focus group participants to evaluate norms and at-
titudes, structure and process, policies and incentives,
resources, networks and linkages, and media and
change agents. Equivalent numbers of follow up ques-
tions (e.g., 1–2) will also be included in the focus
group script to allow for adequate coverage of poten-
tial barriers. The focus group protocols will be stan-
dardized across sites in order to capture comparable
information about barriers to MBC implementation.
Statistical analyses
Quantitative analyses
We will examine mediation models in which contextual
factors (based on clinician-completed surveys, Table 3;
and, clinician selection of reasons for MBC deviations
captured in the electronic health record) mediate the
impact of the implementation condition on both clin-
ician- and client-level outcomes. We will assess differ-
ences in MBC fidelity between conditions by examining
clinician, client, and organizational factors using multi-
level generalized linear models that will provide a gen-
eral framework for assessing group differences for a
variety of outcome distributions (normal, binomial, Pois-
son, etc.) that we anticipate will be necessary to
characterize the factors impacting MBC fidelity. Medi-
ation models will be two-level models (i.e., clinicians
nested within sites) or three-level models (clients nested
within clinician nested within sites) in which outcomes
are measured at the individual level, condition is assigned
at the site level, and mediators are at the clinician or site
level. For assessing mediation in a multilevel context,
models will be constructed following recommendations
from Preacher, Zyphur, and Zhang [55]. To assess medi-
ation, we will test whether (1) implementation condition
predicts the change in the mediator (path a), (2) the medi-
ator predicts growth change in MBC use (path b), (3) con-
dition predicts change in the outcome (path c), and (4)
whether the implementation condition’s effect on MBC
use becomes significantly weaker when controlling for the
mediator (path c’) [56, 57]. We will also apply recommen-
dations from Kraemer, Wilson, Fairburn, and Agras [58]
to demonstrate that change in the mediator precedes
change in MBC use. The indirect effect (i.e., the product
of paths a and b) will be tested using biased-corrected
bootstrapped confidence intervals [59].
Qualitative analyses
Rapid ethnography [60] will be used to synthesize the
needs assessment data in the tailored condition to
characterize participant experiences and to provide effi-
cient data analysis for the purpose of tailoring the MBC
training approach. Focus groups across conditions and
across time points will also be analyzed separately to
characterize participant responses within each site using
a formal coding procedure. We will identify and code
analyzable units of meaning in the focus group tran-
scripts using multiple trained coders to enhance reliabil-
ity. An iterative approach to coding will resolve
disagreements through research team discussion. Codes
will also be assigned based on contextual factors using
the Framework of Dissemination [34]. Inductive analyses
based on emergent themes rooted in grounded theory
will be conducted. The final list of consensus codes will
include themes established a priori and through emer-
gent themes analysis.
Mixed methods analyses
Mixed methods will be used to integrate findings from
Aim 2 using a QUAN + QUAL structure (wherein both
types of data are collected simultaneously) to achieve
the function of data expansion for the purposes of evalu-
ation and elaboration [48]. Using the US NIH guidelines
for mixed methods best practices [61], we will connect
the quantitative and qualitative datasets in QSR N-Vivo
to allow for case-specific pattern identification and hy-
pothesis testing. First, we will enter quantitative MBC fi-
delity data into N-Vivo to categorize sites (within each
condition) into four fidelity groups (categorized as
“none”, “low”, “moderate”, “high”) in order to reveal pat-
terns among the contextual factors that appear to influ-
ence level of MBC fidelity. This approach will allow us
to distinguish factors that might explain the differences
in the quantitative findings, and notably MBC fidelity.
Second, given that both the focus group questions and
the quantitative measures will align with the Framework
for Dissemination [34], we will be able to elaborate on
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the quantitative findings that require further explanation
through the process of expansion using qualitative results.
Power calculations
For Aim 2, we conducted power analyses for the hypoth-
esized mediation effects with the same assumptions de-
scribed above but with the use of effective samples size
estimates (an ICC corrected sample size) based on a de-
sign effect adjustment [62] in order to use standard ef-
fect size metrics. The κ2 effect size for mediation (0.01,
0.09, and 0.25 represent small, medium and large κ2, re-
spectively) was computed [63]. We are sufficiently pow-
ered to detect effect sizes as small as κ2 = 0.16 for the
clinician models and effect sizes as small as κ2 = 0.10 for
the client models.
Aim 3:
To explore the impact of MBC fidelity on client outcomes
thereby testing the DSF [2]
We hypothesize (H3) that adapted MBC protocols (tai-
lored condition) will outperform weekly administration
of PHQ-9s (standardized condition) with respect to clin-
ically significant change in depression severity from in-
take to week 12.
Statistical analysis
We will assess the impact of MBC fidelity (standardized
versus tailored) on clinically significant change observed
in each client between intake and session 12 using gen-
eralized linear mixed models. Models will represent the
three-level structure (i.e., clients are nested within thera-
pists and therapists are nested within sites) with a binary
outcome, representing whether a client exhibited clinic-
ally significant change using the reliable change criterion
[64], modeled with a binomial distribution with a logistic
link function.
Power calculations
For Aim 3 analyses, we are sufficiently powered to detect
effect sizes as small as r = 0.27 for clinicians and as small
as r = 0.21 for clients. The planned sample sizes are con-
sistently sufficient for detecting medium-effect sizes for
clinician outcomes and small effect sizes for client out-
comes, with the power to treat site as a random effect
based on six sites per condition [65].
Trial status
The Indiana University Institutional Review Board has ap-
proved all study procedures. The Pre-Implementation
phase (Phase 0) of the study was completed in May 2015,
and Phase 1 subject recruitment and data collection began
in June 2015 with the first cohort of clinic sites.
Discussion
Innovation
This study is innovative in at least three ways. First, our
focus on testing strategies to implement MBC in com-
munity mental health is innovative because this simple
MBC framework may be the minimal intervention
needed for significantly reducing the burden of depres-
sion on society [11]. For the treatment of depression, we
opted to focus on MBC rather than a complex, theoret-
ically driven EBP like Cognitive Behavioral Therapy not
only because of the MBC implementation gap, but also
because the simplicity and accessibility of the MBC
framework will likely reduce the number of implementa-
tion barriers. Moreover, MBC has been isolated as a core
component of many EBPs. Therefore, identifying effect-
ive implementation strategies for MBC would build the
case for a phased or staged approach to full package
EBP implementation to determine whether later EBP
implementations enhance outcomes beyond improve-
ments observed with MBC.
Second, we will modify the electronic health record
system to provide clinically relevant data to providers
who use MBC, such as symptom trajectory graphs,
alerts when suicidality is endorsed, etc. With electronic
health record prevalence increasing, this approach pre-
sents a generalizable and cost-effective method for en-
gaging in systematic outcome monitoring that maximizes
therapeutic benefit and aligns with meaningful use re-
quirements [66].
Third, the majority of existing implementation re-
search has focused either on descriptive studies that ex-
plore barriers and facilitators (determinants of practice)
or on comparisons of a priori selected implementation
strategies that generally neglect contextual tailoring of
the interventions. A qualitative analysis of 22 implemen-
tation studies revealed that few focused on matching
strategies to determinants of practice [67]. A critical re-
search agenda has emerged seeking to identify, “how and
why implementation processes are effective” [68] by ex-
perimentally evaluating implementations that are tai-
lored to the context. Recent findings support the need to
adapt evidence-based practices during the implementa-
tion process [69, 70], but no studies, to our knowledge,
have directly compared this approach to standardized
EBP implementation.
Limitations
In addition to these and other strengths, this approach
to implementation of MBC has limitations. First, this
implementation effort focuses on outcomes for stan-
dardized and tailored MBC as implemented within mul-
tiple sites of a single behavioral health organization.
While it is anticipated that many of the strategies neces-
sary to facilitate MBC implementation will align with
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previous research efforts, the degree of generalizability
of the standardized and tailored approaches to other
sites and settings is unknown. Second, clinician and cli-
ent turnover across participating clinic sites may limit
the sample size obtained, despite researcher efforts to
exceed recruitment targets. Fortunately, literature sug-
gests that participatory approaches to organizational
change in practice patterns result in lower clinician attri-
tion [71]. Third, the tailored approach to implementa-
tion is site-specific by design and does not allow for the
evaluation of the effectiveness of specific tailored imple-
mentation protocols. Instead, the study approach seeks
to evaluate the effect of tailoring more broadly. However,
the mixed methods component of the study will explore
the variety of MBC tailoring approaches and protocols
utilized by the sites in this study that can be more
closely tested in future research to determine which may
be most effective with respect to implementation and
client outcomes.
Expected impact
Measurement-based care aligns with priorities delin-
eated in the Patient Protection and Affordable Care Act
(P.L. 111–148), notably systematic evaluation of ser-
vices [16] and meaningful use requirements of elec-
tronic health records; however, systematic monitoring
of client/consumer outcomes remains a challenge for
providers of community-based mental health services.
This study has the potential to impact public health
through identification of practical and generalizable ap-
proaches to implementing MBC into CMHCs. More-
over, the evaluation of contextual mediators across 12
diverse Centerstone sites may reveal common barriers
to be directly addressed in future research. Evidence-
based intervention frameworks, such as MBC, are
rarely the focus of implementation efforts. Thus, unco-
vering unique or previously identified contextual fac-
tors impacting implementation is critical to advancing
implementation science. Finally, exploring MBC fidelity
and its relation to client outcomes may reveal a “min-
imal intervention needed for change” (MINC; [15]) and
the mechanisms through which MBC has an effect.
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